Equity Profile

SMMT

Summit Therapeutics Inc.

Health CareBiotechnology$10.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing novel medicines to treat serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and acceptance of its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing novel medicines to treat serious diseases. With a market cap of $10 billion, it operates in the health care sector, which is increasingly important as the demand for innovative therapies grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, outperforming expectations by nearly 55%. The stock reacted positively, gaining over 3% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to cost management strategies.
Plans to enhance product pipeline.

Expectations

Wall Street Expectations

Overall expectations for Summit Therapeutics are mixed, with investors looking for signs of progress in clinical trials and financial performance.

Bull Case

If the company reports better-than-expected EPS and shows significant advancements in clinical trials, it could lead to strong investor confidence and stock price appreciation.

Bear Case

Conversely, if the company fails to meet EPS expectations or reports delays in clinical trials, it could lead to a decline in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in determining the company's financial health and could influence stock performance significantly.

What updates will be provided on clinical trial progress?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can greatly affect future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of recent advancements in clinical trials, which could lead to better-than-expected results this quarter.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that investors are anticipating volatility and potential positive news.

Recent positive trends in clinical trial outcomes may not be fully reflected in current market sentiment.

Key Risk

If clinical trial updates indicate faster progress than expected, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the balance between financial results and clinical advancements, which are both critical for investor confidence.

Bull Confirmed If

A reported EPS of -$0.10 or better, along with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.20, combined with delays in clinical trials, would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests a potential stock increase of around 5.8%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline of about 1.4%, as seen in past performances when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific numbers related to the EPS for Q2-2026.
2Updates on the status and results of ongoing clinical trials.
3Management's commentary on cost management strategies.
4Insights into the product pipeline and future plans.
5Any changes in guidance or expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing novel medicines to treat serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and acceptance of its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, outperforming expectations by nearly 55%. The stock reacted positively, gaining over 3% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to cost management strategies.
Plans to enhance product pipeline.

Expectations

Wall Street Expectations

Overall expectations for Summit Therapeutics are mixed, with investors looking for signs of progress in clinical trials and financial performance.

Bull Case

If the company reports better-than-expected EPS and shows significant advancements in clinical trials, it could lead to strong investor confidence and stock price appreciation.

Bear Case

Conversely, if the company fails to meet EPS expectations or reports delays in clinical trials, it could lead to a decline in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in determining the company's financial health and could influence stock performance significantly.

What updates will be provided on clinical trial progress?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can greatly affect future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of recent advancements in clinical trials, which could lead to better-than-expected results this quarter.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that investors are anticipating volatility and potential positive news.

Recent positive trends in clinical trial outcomes may not be fully reflected in current market sentiment.

Key Risk

If clinical trial updates indicate faster progress than expected, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the balance between financial results and clinical advancements, which are both critical for investor confidence.

Bull Confirmed If

A reported EPS of -$0.10 or better, along with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.20, combined with delays in clinical trials, would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests a potential stock increase of around 5.8%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline of about 1.4%, as seen in past performances when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific numbers related to the EPS for Q2-2026.
2Updates on the status and results of ongoing clinical trials.
3Management's commentary on cost management strategies.
4Insights into the product pipeline and future plans.
5Any changes in guidance or expectations for the upcoming quarters.